Adrenal insufficiency due to high doses of maternal corticosteroid treatment in a premature baby

BMJ Case Rep. 2022 Aug 3;15(8):e246961. doi: 10.1136/bcr-2021-246961.

Abstract

Adrenal insufficiency (AI) in a newborn due to hypothalamic-pituitary-adrenal (HPA) axis suppression after maternal glucocorticoid therapy during pregnancy is a rare condition. We report an AI triggered by a nosocomial infection in a premature newborn. The suspected mechanism was the suppression of the HPA axis due to high doses of maternal glucocorticoid treatment during pregnancy. AI was revealed by recurrent hypoglycaemia and mild hyponatraemia during the neonatal period. His twin brother did not develop AI, showing the variable sensitivity of adrenal suppression after exposure to the same glucocorticoid dose. The affected boy was substituted with hydrocortisone until the age of 2 years. At this age, basal morning values for cortisol and Adrenocorticotropic hormone (ACTH) had normalised. The patient also suffers from galactosaemia. We suggest screening for AI, by testing for hypoglycaemia and hyponatraemia, in newborns who were exposed to high doses of maternal methylprednisolone treatment during the pregnancy and to include galactosaemia in national neonatal screening programmes.

Keywords: adrenal disorders; congenital disorders.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Insufficiency* / chemically induced
  • Adrenal Insufficiency* / diagnosis
  • Adrenal Insufficiency* / drug therapy
  • Child, Preschool
  • Galactosemias* / drug therapy
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydrocortisone
  • Hypoglycemia* / chemically induced
  • Hypoglycemia* / drug therapy
  • Hyponatremia* / drug therapy
  • Hypothalamo-Hypophyseal System
  • Infant
  • Infant, Newborn
  • Infant, Premature, Diseases* / drug therapy
  • Male
  • Pituitary-Adrenal System

Substances

  • Glucocorticoids
  • Hydrocortisone